主页 > 医学信息 >
【medical-news】阿糖腺苷A2A 受体与左旋多巴诱导的
Main Category: Neurology / Neuroscience News
Article Date: 01 Jan 2007 - 0:00 PST
Treatment of Parkinson's disease with L-3,4- dihydroxyphenylalanine (L-DOPA) has its limits. Continued treatment often leads to adaptive behavioral responses and, in particular, involuntary movements referred to as L-DOPA- induced-dyskinesia (LID). Because adenosine A2A receptors are highly expressed in striatum, there has been interest in their use in nondopaminergic treatments.
Xiao et al. wanted to know whether blocking A2A receptor signaling would relieve symptoms of LID in hemiparkinsonian mice. Using the Cre/lox system, the authors knocked out A2A receptors in the forebrains of transgenic mice.
These mice developed fewer abnormal involuntary movements and rotational responses during chronic L-DOPA treatment, similar to mice that received low doses of A2A receptor antagonists along with L-DOPA.
Thus A2A receptors in forebrain neurons may contribute to the behavioral sensitization to L-DOPA, perhaps indicating that A2A antagonists could reduce the risk of LID.
Danqing Xiao, Elena Bastia, Yue-Hang Xu, Caroline L. Benn, Jang-Ho J. Cha, Tracy S. Peterson, Jiang-Fan Chen, and Michael A. Schwarzschild
Written by: Sara Harris
Society for Neuroscience
News tips from the Journal of Neuroscience
http://www.medicalnewstoday.com/medicalnews.php?newsid=59829 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领 Adenosine A2A Receptors And L-DOPA-Induced Dyskinesia
阿糖腺苷A2A受体与左旋多巴诱导的运动障碍
Main Category: Neurology / Neuroscience News
Article Date: 01 Jan 2007 - 0:00 PST
主目录：神经病学/神经系统科学新闻
刊文时间：01 Jan 2007 - 0:00 PST
Treatment of Parkinson's disease with L-3,4- dihydroxyphenylalanine (L-DOPA) has its limits. Continued treatment often leads to adaptive behavioral responses and, in particular, involuntary movements referred to as L-DOPA- induced-dyskinesia (LID). Because adenosine A2A receptors are highly expressed in striatum, there has been interest in their use in nondopaminergic treatments.
运用L-3,4- dihydroxyphenylalanine（左旋多巴）临床治疗帕金森有其不足之处。持续性的治疗经常导致适应性行为反应，尤其是称为左旋多巴诱导性运动障碍(LID)的不自主运动。由于阿糖腺苷A2A受体在纹状体高度表达，它们在非多巴胺的治疗中的作用一直受到关注。
Xiao et al. wanted to know whether blocking A2A receptor signaling would relieve symptoms of LID in hemiparkinsonian mice. Using the Cre/lox system, the authors knocked out A2A receptors in the forebrains of transgenic mice.
Xiao等希望了解是否阻断阿糖腺苷A2A受体信号系统可减轻半侧帕金森小鼠的LID症状。使用Cre/lox系统，作者敲除了转基因小鼠额叶的阿糖腺苷A2A受体。
These mice developed fewer abnormal involuntary movements and rotational responses during chronic L-DOPA treatment, similar to mice that received low doses of A2A receptor antagonists along with L-DOPA.
这些小鼠在长期左旋多巴治疗过程中表现出较少的异常不自主运动以及轮替反应，与接受低剂量阿糖腺苷A2A受体拮抗剂加左旋多巴处理的小鼠类似。
Thus A2A receptors in forebrain neurons may contribute to the behavioral sensitization to L-DOPA, perhaps indicating that A2A antagonists could reduce the risk of LID.
额叶神经细胞的阿糖腺苷A2A受体可能导致对左旋多巴的行为的敏感性，也许表明阿糖腺苷A2A受体拮抗剂能够降低LID的风险。
Danqing Xiao, Elena Bastia, Yue-Hang Xu, Caroline L. Benn, Jang-Ho J. Cha, Tracy S. Peterson, Jiang-Fan Chen, and Michael A. Schwarzschild
Written by: Sara Harris
Society for Neuroscience
News tips from the Journal of Neuroscience [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-13 17:11
医学,生命科学网